PRRSV Minor Protein Adenovirus Vectors for Safer Broad Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PRRSV vaccines, particularly recombinant vaccines based on major envelope proteins, fail to provide broad protection against various viral variants and are either unsafe or ineffective, with live vaccines risking reversion to wild-type and killed vaccines offering limited efficacy.
Innovation Solution
Development of recombinant adenovirus-vectored vaccines expressing PRRSV minor proteins gp2, gp3, and gp4, with modifications to ensure cell-surface expression, using vectors like Ad5, baculovirus, or poxvirus, to form protective protein complexes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If attenuated modified live virus vaccines are used, then effective protection against homologous challenge is achieved, but safety deteriorates due to potential reversion to wild-type and inability to achieve PRRSV-free status
Solution Approach 1:
The patent extracts only the essential immunogenic components (minor envelope proteins gp2, gp3, gp4) from the complete live virus, eliminating the replication-competent genome while retaining the protective antigens. This creates a subunit vaccine that provides immunogenicity without the safety risks of live virus reversion.
Solution Approach 2:
The patent uses an adenovirus vector as an intermediary delivery system to present the PRRSV minor proteins to the immune system. This mediator approach allows the antigens to be delivered and expressed in a controlled manner without using the actual PRRSV live virus, thus avoiding safety risks while maintaining efficacy.
2Object-affected harmful factors
If killed virus vaccines are used, then safety is improved, but protection efficacy deteriorates due to limited immunogenicity
Solution Approach 1:
The patent changes the molecular form and presentation of the viral antigens by expressing minor envelope proteins as recombinant fusion proteins with cell surface localization signals. This parameter change in antigen structure and cellular localization enhances immunogenicity significantly compared to traditional killed whole virus vaccines, achieving both safety and efficacy.
Solution Approach 2:
The patent creates composite antigen structures by fusing PRRSV minor proteins with heterologous cell surface localization sequences (such as VSV-G transmembrane and cytoplasmic domains). These composite proteins are then presented on the surface of transfected cells, creating a composite vaccine system that combines safety with enhanced immunogenicity.
3Ease of manufacture
If recombinant vaccines based on major envelope proteins are used, then ease of manufacture is improved, but protection efficacy deteriorates due to lack of broad protection against variants
Solution Approach 1:
Instead of focusing on the major envelope proteins (gp5, M) as traditionally done, the patent inverts the approach by targeting the minor envelope proteins (gp2, gp3, gp4). This inversion reveals that the minor proteins, which are more conserved and mediate receptor binding, provide broader cross-protection against different PRRSV variants while remaining feasible to produce recombinantly.
Data Source
Figure 1A~1D
Figure 1E~1G
Figure 2~3
AI summary
The present invention encompasses recombinant porcine reproductive and respiratory syndrome virus (PRRSV) vaccines or compositions. In particular, the invention encompasses recombinant adenovirus vectors encoding and expressing PRRSV gp2, gp3, gp4, gp5a, gp5 and/or E antigens, proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals from PRRSV.